EP689 Cytoreduction and hyperthermic intraperitoneal chemotherapy followed by hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) in advanced peritoneal carcinomatous (APC) at the american university of beirut medical center (AUBMC) experience 2007–2018: a retrospective review. (1st November 2019)
- Record Type:
- Journal Article
- Title:
- EP689 Cytoreduction and hyperthermic intraperitoneal chemotherapy followed by hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) in advanced peritoneal carcinomatous (APC) at the american university of beirut medical center (AUBMC) experience 2007–2018: a retrospective review. (1st November 2019)
- Main Title:
- EP689 Cytoreduction and hyperthermic intraperitoneal chemotherapy followed by hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) in advanced peritoneal carcinomatous (APC) at the american university of beirut medical center (AUBMC) experience 2007–2018: a retrospective review
- Authors:
- Abdallah, R
Seoud, M
El Housheimi, A
Shamseddine, A
Khalifeh, M
Jaafar, I
Jamali, F - Abstract:
- Abstract : Introduction/Background: Peritoneal carcinomatosis (PC) has been traditionally considered a terminal disease with median survivals reported in literature of 6–12 months. Cytoreductive surgery (CRS) & hyperthermic intra-peritoneal chemo-therapy (HIPEC) have gradually gained acceptance as standard of care to manage selected PC cases. Our objective is to review the outcome of patients with APC who underwent CRS+HIPEC by the HIPEC team at the AUBMC Methodology: All patients with APC were evaluated by the HIPEC team for eligibility and the majority had either gastrointestinal or gynecological malignancies. We retrospective reviewed data related to their demographics/tumor origin/surgical completeness/adverse events/outcome Results: Since 2007, 53 patients (45% were females) were had CRS and HIPEC. 20 (37.6%) had Pseudomyxoma peritonei (PMP), 12 (23%) ovarian cancer, 14 (26.4%) colorectal cancer, 4 (7.5%) had gastric cancer, 2 (3.7%) had Mesothelioma and one (1.8%) Desmoplastic round cell tumor. Operative and Postoperative demographics and survivals are shown in tables 1 and 2. Median progression free (PFS) and overall survival (OS) are expressed in months. Conclusion: We report the successful establishment of an active peritoneal surface malignancy multidisciplinary treatment program with results comparable to other centers. Careful patient selection, a multidisciplinary approach and proper surgical training and technique are essential for the success of such aAbstract : Introduction/Background: Peritoneal carcinomatosis (PC) has been traditionally considered a terminal disease with median survivals reported in literature of 6–12 months. Cytoreductive surgery (CRS) & hyperthermic intra-peritoneal chemo-therapy (HIPEC) have gradually gained acceptance as standard of care to manage selected PC cases. Our objective is to review the outcome of patients with APC who underwent CRS+HIPEC by the HIPEC team at the AUBMC Methodology: All patients with APC were evaluated by the HIPEC team for eligibility and the majority had either gastrointestinal or gynecological malignancies. We retrospective reviewed data related to their demographics/tumor origin/surgical completeness/adverse events/outcome Results: Since 2007, 53 patients (45% were females) were had CRS and HIPEC. 20 (37.6%) had Pseudomyxoma peritonei (PMP), 12 (23%) ovarian cancer, 14 (26.4%) colorectal cancer, 4 (7.5%) had gastric cancer, 2 (3.7%) had Mesothelioma and one (1.8%) Desmoplastic round cell tumor. Operative and Postoperative demographics and survivals are shown in tables 1 and 2. Median progression free (PFS) and overall survival (OS) are expressed in months. Conclusion: We report the successful establishment of an active peritoneal surface malignancy multidisciplinary treatment program with results comparable to other centers. Careful patient selection, a multidisciplinary approach and proper surgical training and technique are essential for the success of such a program. Disclosure: Nothing to disclose. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 29(2019)Supplement 4
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 29(2019)Supplement 4
- Issue Display:
- Volume 29, Issue 4 (2019)
- Year:
- 2019
- Volume:
- 29
- Issue:
- 4
- Issue Sort Value:
- 2019-0029-0004-0000
- Page Start:
- A394
- Page End:
- A394
- Publication Date:
- 2019-11-01
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2019-ESGO.743 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19762.xml